Dimethyl fumarate
- Generic Name
- Dimethyl fumarate
- Brand Names
- Tecfidera, Skilarence, Dimethyl fumarate Neuraxpharm, Dimethyl fumarate Mylan, Dimethyl fumarate Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8O4
- CAS Number
- 624-49-7
- Unique Ingredient Identifier
- FO2303MNI2
- Background
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-...
- Indication
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Relapsing Forms of MS, Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 54
- Registration Number
- NCT02959658
- Locations
- 🇩🇰
Danish Multiple Sclerosis Center, Department of neurology, Copenhagen, Denmark
Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Target Recruit Count
- 11
- Registration Number
- NCT02901106
- Locations
- 🇫🇷
Fondation Ophtalmique Adolphe de Rothschild, Paris, France
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Michael Choi
- Target Recruit Count
- 2
- Registration Number
- NCT02784834
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
- Conditions
- Interventions
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Anders Svenningsson
- Target Recruit Count
- 200
- Registration Number
- NCT02746744
- Locations
- 🇸🇪
Fredrik Piehl, Stockholm, Sweden
🇸🇪South Älvsborg Hospital, Borås, Sweden
🇸🇪Falun Hospital, Falun, Sweden
Impact of Tecfidera on Gut Microbiota
- Conditions
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Virginia Simnad
- Target Recruit Count
- 25
- Registration Number
- NCT02736279
- Locations
- 🇺🇸
EvergreenHealth MS Center, Kirkland, Washington, United States
Tecfidera Diffusion Tensor Imaging
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 115
- Registration Number
- NCT02686684
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
- Conditions
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02675413
- Locations
- 🇺🇸
Swedish Neuroscience Institute, Seattle, Washington, United States
🇺🇸Washington University (John L. Trotter MS Center), St. Louis, Missouri, United States
Tecfidera and MRI for Brain Energy in MS
- Conditions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 4
- Registration Number
- NCT02644083
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 221
- Registration Number
- NCT02579681
- Locations
- 🇮🇹
Research site, Roma, Italy
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT02555215
- Locations
- 🇹🇷
Research Site, Ankara, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.